Matrix-assisted laser desorption/ionization mass spectrometry imaging to uncover protein alterations associated with the progression of IgA nephropathy

被引:0
作者
Mariia Ivanova
Olena Dyadyk
Dmytro Ivanov
Francesca Clerici
Andrew Smith
Fulvio Magni
机构
[1] University of Milano-Bicocca,Department of Medicine and Surgery, Clinical Proteomics and Metabolomics Unit
[2] Bogomolets National Medical University,undefined
[3] P.L. Shupyk National Medical Academy of Postgraduate Education (NMAPE),undefined
来源
Virchows Archiv | 2020年 / 476卷
关键词
IgA nephropathy; Mesangioproliferative glomerulonephritis; Chronic kidney disease; MALDI-MSI; Mass spectrometry; Proteomics;
D O I
暂无
中图分类号
学科分类号
摘要
IgA nephropathy (IgAN) is one of the most diffuse glomerulonephrites worldwide, and many issues still remain regarding our understanding of its pathogenesis. The disease is diagnosed by renal biopsy examination, but potential pitfalls still persist with regard to discriminating its primary origin and, as a result, determining patient outcome remains challenging. In this pilot study, matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) was performed on renal biopsies obtained from patients with IgAN (n = 11) and other mesangioproliferative glomerulonephrites (MesPGN, n = 6) in order to enlighten proteomic alterations that may be associated with the progression of IgAN. Differences in the proteomic profiles of IgAN and MesPGN tissue could clearly be detected using this approach and, furthermore, 14 signals (AUC ≥ 0.8) were observed to have an altered intensity among the different CKD stages within the IgAN group. In particular, large increases in the intensity of these signals could be observed at CKD stages II and above. These signals primarily corresponded to proteins involved in either inflammatory and healing pathways and their increased intensity was localized within regions of tissue with large amounts of inflammatory cells or sclerosis. Despite much work in recent years, our molecular understanding of IgAN progression remains incomplete. This pilot study represents a promising starting point in the search for novel protein markers that can assist clinicians in better understanding the pathogenesis of IgAN and highlighting those patients who may progress to end-stage renal disease.
引用
收藏
页码:903 / 914
页数:11
相关论文
共 243 条
  • [1] Bartosik LP(2012)clinical practice guidelines for glomerulonephritis. Chapter 1: introduction Kidney Int Suppl 2 156-162
  • [2] Lajoie G(2012)clinical practice guidelines for glomerulonephritis. Chapter 2: general principles in the management of glomerular disease Kidney Int Suppl 2 156-162
  • [3] Sugar L(2001)Predicting progression in IgA nephropathy Am J Kidney Dis 38 728-735
  • [4] Cattran DC(2001)Predicting prognosis in IgA nephropathy Am J Kidney Dis 38 728-735
  • [5] Feehally J(2018)Was ist gesichert in der Therapie der Glomerulonephritis? Internist (Berl) 59 1268-1278
  • [6] Floege J(2018)New insights into the pathogenesis of IgA nephropathy Pediatr Nephrol 33 763-777
  • [7] Boor P(2018)Biomarkers and precision medicine in IgA nephropathy Semin Nephrol 38 521-530
  • [8] Moeller MJ(2016)Biomarkers and targeted new therapies for IgA nephropathy Pediatr Nephrol 32 725-731
  • [9] Yeo SC(2017)The putative role of MALDI-MSI in the study of membranous nephropathy Biochim Biophys Acta, Proteins Proteomics 1865 865-874
  • [10] Cheung CK(2017)Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis Sci Rep 7 9091-906